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Dear Editor,
The severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) pandemic has 
been a major disruptive event for the global 
oncology community. It has challenged 
and compromised the delivery of oncolog-
ical care as a result of (1) the diversion of 
resource to support the care of acutely and 
critically ill patients with COVID-19; (2) a 
reduction in the number of highly trained 
staff who deliver such treatments due to sick-
ness, self- isolation or family reasons1; and (3) 
concerns related to treating patients with 
cancer, given issues related to the potential 
risks of acquiring SARS- CoV-2 and the degree 
of severity of COVID-19 as a result of either 
innate or iatrogenic cancer- related immuno-
deficiency. The current peer- reviewed data 
regarding the course of COVID-19 in patients 
with cancer is limited to retrospective cases 
series of 11–105 patients with variability in 
the data reported2–6 and one study involving 
aggregate- level data from 334 patients.7 These 
datasets do not enable the identification of 
risk factors that might predispose to symp-
tomatic SARS- CoV-2 infection nor do they 
identify those factors that predict for serious 
morbidity and mortality as a result of infec-
tion. Such information is urgently needed to 
inform the development of a robust evidence 
base approach to risk stratification by tumour 
and treatment type, as well as development 
and introduction of appropriate mitigation 
measures.
It is in response to this information vacuum 
that a number of cancer- specific observational 
studies and audits have been developed in an 
organic and parallel manner (table 1). These 
studies cover surgical, oncological and psycho-
logical aspects of COVID-19. They range from 
the collection of data on all cancers to infor-
mation on specific cancers; most are retro-
spective, involving a single specialist group. 
Some do take a cross specialty approach and 
enable comparison to non- cancer cohorts, 
as well as enable translational research from 
biological samples (table 1). In addition to 
these, there are audits led by specialist soci-
eties, such as Intensive Care National Audit 
and Research Centre, which provide some 
information on cancer cases with the poten-
tial to be analysed in great detail and to allow 
comparison with patients without cancer.8 
The International Severe Acute Respira-
tory and Emerging Infections Consortium 
WHO Clinical Characterisation Protocol has 
collected detailed clinical information and 
outcomes for over 30 000 people of all ages 
admitted to hospitals with COVID-19 and has 
recorded major comorbidities and concom-
itant medications that identify those people 
affected by cancer.9
It is key that all these important efforts 
culminate in a robust evidence which can 
enable1 governments and policy makers to 
provide clear advice regarding the need or 
otherwise for patients with cancer to self- 
isolate/cocoon, as well as to identify groups 
to prioritise for vaccination or other evidence- 
based interventions which might reduce the 
severity of infection2; oncologists to provide 
clear advice regarding the risks of specific 
treatment modalities and systemic anti-
cancer therapy for specific cancers in the era 
of SARS- CoV-2 and3 patients to make more 
informed decisions regarding their cancer 
care and the degree they choose interact and 
mix at societal and family levels. The latter is 
particularly important for patients with life- 
limiting diagnoses, as well as for addressing 
the mental health effects of self- isolation.10
To enable this and to ensure we harness 
the true potential of all these data, we wish to 
suggest the adoption of what we have named 
‘principles for collaboration in the field of 
cancer and COVID-19’. These principles are 
(1) the establishment of a searchable data-
base of all non- IMP (Investigational medicinal 
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Table 1 Summary of the current cancer observational and translational studies related to the SARS- CoV-2/COVID-19 
pandemic
Name of study/location Brief description
CovidSurg–Cancer/global Observational
Evaluate the 30- day COVID-19 infection rates in elective cancer surgery during the 
COVID-19 pandemic (https://globalsurg.org/cancercovidsurg/)
The COVID-19 and Cancer 
Consortium
The USA, the European Union, 
Argentina, Canada and the UK are 
eligible to participate. Currently, 
there are 100 USA centres.
Observational
Aim is to collect data about patients with cancer who have been infected with COVID-19 
(https://ccc19.org/)
American Society of Haematology 
Research Collaborative
COVID-19 Registry for 
Hematologic Malignancy/global
Observational
Captures data on people who test positive for COVID-19 and have been or are currently 
being treated for hematological malignancy (https://www.ashresearchcollaborative.org/
covid-19-registry)
Thoracic Cancers International 
COVID-19 Collaboration/global
Observational
A global consortium designed to gather information on patients with thoracic cancer 
infected with COVID-19 regardless of therapies administered (http://www.etop-eu.org/
index.php?option=com_content&view=article&id=115644&catid=13&Itemid=557)
Clinical Characterisation Protocol–
Cancer UK/UK
Prospective observational and biological samples
The study will characterise the presentation, management and outcome of patients 
with solid and haematological malignancies recruited into the prospective Clinical 
Characterisation Protocol for Severe Emerging Infections in the UK. It will also compare 
patients with cancer to those without cancer. The biology of SARS- CoV-2 in the context of 
cancer- associated or iatrogenic immunosuppression will also be investigated (https://isaric.
tghn.org/UK-CCP/)
UK Coronavirus Cancer 
Monitoring Project/UK
Observational
The UK Coronavirus Cancer Monitoring scheme is a clinician- led reporting project recoding 
data related to patients with cancer who have tested positive for COVID-19 across the UK 
(https://ukcoronaviruscancermonitoring.com/).
Paediatrics (https://ukcoronaviruscancermonitoring.com/paediatrics/)
ONCOVID/UK, Italy and Spain Observational
To describe the features of COVID-19 infection in patients with cancer, investigate its 
severity in this population and evaluate long- term outcomes (https://www.oncovid.net/)
UK COVID and Gynaecological 
Cancer Study/UK
Observational
Records and assesses changes and outcomes in patients across the whole patient 
pathway and within the multidisciplinary team context
bb- ukcogs@qmul.ac.uk
Patients with AML and COVID-19 
Epidemiology/UK
Observational
Aims to understand the incidence, presentation and severity of COVID-19 during treatment 
of AML As well as to develop informed recommendations for the care of patients with AML, 
including those who develop COVID-19 infection during treatment or have recovered from 
prior COVID-19 infection
COVID- RT
Clinicaland Translational 
Radiotherapy (CT- RAD) Research 
Working Group, UK
Observational
Aimsto capture changes in radiotherapy pathways and understand their impact 
onradiotherapy services and patient outcomes across the UK. The initiative willnot only 
focus on patients with COVID-19, but all radiotherapy patients (https://www.ncri.org.uk/
news/covid19-radiotherapy-initiative/)
The American Society of Clinical 
Oncology Survey on COVID-19 in 
Oncology Registry/USA
Observational
Captures baseline and follow- up data on how the impact of SARS- CoV-2 on cancer care 
and cancer patient outcomes during the COVID-19 pandemic and into 2021
Psychology study/China Observational
The effects of prevention and control measures on treatment and psychological status of 
patients with cancer during the COVID-19 outbreak (http://www.chictr.org.cn/showproj.
aspx?proj=50714)
Continued
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Name of study/location Brief description
Clinically related study/China Observational/retrospective
Clinical characteristics and prognosis of patients with cancer with COVID-19 based on 
bioinformatics analysis
(http://www.chictr.org.cn/showproj.aspx?proj=51019)
Perioperative immune prediction 
and intervention of patients with 
tumour undergoing surgery during 
the COVID-19 outbreak period/
China
Interventional/prospective
To understand the influence of the pandemic on the prognosis of patients undergoing 
cancer surgery and to understand the influence of different interventions on outcomes 
(http://www.chictr.org.cn/showproj.aspx?proj=50984).
AML, acute myeloid leukemia; SARS- CoV-2, severe acute respiratory syndrome coronavirus 2.
Table 1 Continued
products) COVID-19 cancer studies with all protocols and 
documents being made available; (2) enabling patients 
with cancer to register and contribute their own data and 
biological material if they so wish; (3) establishment of 
an agreed core cancer COVID-19 dataset with accepted 
common definitions, such as defining events and severity 
of infection; (4) the involvement of experts in infec-
tious disease, microbiology, infection control and crit-
ical care in all projects, given the cross- cutting nature of 
COVID-19 and the need to capture relevant data across 
theses specialities; (5) agreement to bring all datasets 
together for a meta- analysis; and (6) the creation of a 
public facing open- access repository of all data for future 
research and policymaking. We hope that the oncology–
COVID research community that has developed since the 
inception of the pandemic can cooperate and coordinate 
using these principles for the benefit of our patients and 
society.
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